What happened: 2 Healthcare Stocks to Buy Ahead of the New Year
CRISPR's partnership with Vertex reduces development risk and provides cash flow. | Vertex's diversified product base and strong cash generation enable continued R&D investment.
CRISPR Therapeutics could soar on significant pipeline progress and upcoming U.S. approvals.
Why it matters: This development reflects the current expansion phase with bullish market trends and medium volatility levels. Moderate impact on consumer spending
Market Impact: Market-moving development with medium volatility impact and bullish trend implications across 1 sectors.
Simple takeaway: This high-impact development requires immediate attention and may warrant portfolio adjustments.
#Healthcare #Biotech #Stocks #Investing #Gene Editing
What happened: 'Godmother of AI' says degrees are less important in hiring than 'how quickly can you superpower yourself' with new tools | Fortune
The tech industry is facing a shortage of skilled workers in AI and machine learning | Online courses and boot camps are not enough to train employees in AI
Fei-Fei Li values AI skills over college degrees
Why it matters: This development reflects the current expansion phase with bullish market trends and high volatility levels. Moderate impact on consumer spending
Market Impact: Market-moving development with high volatility impact and bullish trend implications across 1 sectors.
Simple takeaway: This high-impact development requires immediate attention and may warrant portfolio adjustments.
#AI #Machine Learning #Tech Startup #Fei-Fei Li